# Thoracic Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN-TD
- Date: 1979-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ngozi Halvorsen-Pierce, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Clarence Whitfield-Arroyo, MD

## Reason for consultation

Lung-RADS 4X nodule on a first low-dose screening CT in a 65-year-old man who smokes a pack a day (35 pack-years): a solid, spiculated 2.9 cm left upper lobe nodule with an enlarged 1.6 cm left hilar node. PET-CT and brain MRI are booked this week and EBUS staging after that. Please see him within two weeks to review the results with him and plan treatment if this is cancer. **S**

## History

Mr. Owens, 65, is seen at the request of Dr. Whitfield-Arroyo 15 days after his first low-dose screening CT showed a Lung-RADS 4X left upper lobe nodule and an enlarged left hilar node. Since then he has had PET-CT, brain MRI, endobronchial ultrasound with node sampling, and pulmonary function tests this morning, and our thoracic tumor board reviewed him five days ago. He has a long-standing morning cough and no other symptoms. He smokes a pack a day, 35 pack-years, and says he is ready to stop. He is fully active (ECOG 0). **S**

## Examination

| System | Finding |
|---|---|
| General | Well and upright; weight 76.6 kg; blood pressure 130/80, pulse 80; oxygen saturation 95 percent; ECOG 0 |
| Lymph nodes | No supraclavicular or cervical nodes |
| Respiratory | Scattered rhonchi that clear with a cough; no wheeze |
| Extremities | No clubbing |

BP 130/80 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 76.6 kg; BMI 24.2 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Whitfield-Arroyo's intake note and results. Screening CT: 2.9 cm solid spiculated nodule in the apicoposterior left upper lobe; 1.6 cm left hilar node; mild upper-lobe emphysema; coronary calcification. FDG PET-CT: avid nodule (SUVmax 9.8) and avid 11L node (SUVmax 6.1); no mediastinal, supraclavicular or distant uptake. Brain MRI: no metastases. EBUS with systematic sampling: adenocarcinoma in 11L, TTF-1 positive; 4R, 4L, 7 and 10L negative with adequate lymphocytes. PD-L1 (22C3) 40 percent. Tissue sequencing with concordant plasma testing: KRAS G12C; STK11 and KEAP1 wild type; no EGFR, ALK, ROS1, BRAF V600E, MET exon 14, RET, NTRK or HER2 alteration. Pulmonary function today: FEV1 2.71 L (86 percent predicted), FEV1/FVC 0.73, DLCO 86 percent predicted. Today's blood count, creatinine 1.0 mg/dL, liver tests, TSH 1.9 and morning cortisol 13.8 are normal. Hemoglobin: 14.9 g/dL; White cell count: 8.1 10*3/uL; Absolute neutrophil count: 5.2 10*3/uL; Platelets: 258 10*3/uL; Creatinine: 1 mg/dL; eGFR (CKD-EPI 1974): 84 mL/min/1.73 m²; Glucose: 97 mg/dL; ALT: 23 U/L; AST: 22 U/L; Total bilirubin: 0.6 mg/dL; TSH: 1.9 mIU/L; Free T4: 1.2 ng/dL; Morning cortisol: 13.8 ug/dL; FEV1: 2.71 L; FEV1 percent predicted: 86%; FEV1/FVC: 0.73; DLCO: 23.6 mL/min/mm[Hg]; PHQ-9: 6; GAD-7: 7. All results are synthetic.

## Assessment

1. **Adenocarcinoma of the left upper lobe, cT1c N1 M0, stage IIB, resectable** (C34.12). Question 1: this is lung adenocarcinoma, stage IIB (AJCC 8th edition): a 2.9 cm primary with a positive interlobar node and negative mediastinal stations on systematic EBUS sampling (4R, 4L and 7 plus 10L), as ACCP guidance advises when a hilar node is positive; PET-CT and brain MRI complete the staging, and no mediastinoscopy is needed. Question 2: it is resectable by lobectomy. Because EGFR and ALK are negative, the tumor board recommends three cycles of nivolumab with carboplatin and pemetrexed before surgery (CheckMate 816), which improved event-free survival and the rate of pathologic complete response over surgery alone without making surgery less feasible, then thoracoscopic left upper lobectomy with systematic node dissection. Question 3: EGFR and ALK had to be excluded first, because targeted therapy, not chemoimmunotherapy, would be preferred around surgery if either were present; PD-L1 of 40 percent supports immunotherapy. KRAS G12C does not change treatment for resectable disease but makes sotorasib or adagrasib options if it ever recurs. **S**
2. **Nicotine dependence, cigarettes** (F17.210). Question 5: stopping smoking now lowers the risk of complications after surgery and the risk of recurrence and second cancers, and improves survival; it is part of his cancer treatment. Varenicline with counseling is the most effective approach. **S**

## Recommendations

1. Three cycles of nivolumab 360 mg with carboplatin AUC 5 and pemetrexed 500 mg/m2 every three weeks, starting in about a week; folic acid and vitamin B12 first; dexamethasone around each pemetrexed dose; hepatitis B, hepatitis C and HIV tests before cycle 1.
2. Restaging CT of the chest and upper abdomen after cycle 3, then thoracoscopic left upper lobectomy with systematic mediastinal and hilar node dissection about five weeks after the last cycle.
3. Question 4: he is fit for lobectomy. Predicted postoperative FEV1 and DLCO are both about 63 percent, above 60 percent, so no exercise test is needed (ACCP). Prehabilitation in a pulmonary rehabilitation program during chemotherapy, and rehabilitation again after surgery.
4. Immune-related adverse event monitoring before each cycle: blood count, TSH, free T4, liver tests, creatinine and glucose, with morning cortisol at baseline and before each infusion; a written list of warning symptoms (new cough or breathlessness, diarrhea, rash, yellowing, severe tiredness or headache) and the 24-hour oncology line.
5. Varenicline from today with a quit date on the day of cycle 1, the quitline, and tobacco review at every visit.
6. After surgery, decide on further treatment from the pathology: with a major pathologic response and negative nodes, surveillance is reasonable, since this regimen was given before surgery only; then chest CT every six months for two to three years and yearly low-dose CT afterwards, with no routine PET-CT, brain MRI or tumor markers.
7. Question 6: primary care to share symptom, mood and distress screening, tobacco support, vaccinations (pneumococcal vaccine before treatment) and the preventive care due at his age. Specialist palliative care is not needed now for a cancer treated with curative intent and causing no symptoms; we will refer if needs arise.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Whitfield-Arroyo the same day and presented at the thoracic tumor board with surgery, radiology and pathology. The images, the stage and the aim of cure were explained to Mr. Owens in plain words, with written next steps and a nurse navigator's number; he chose to start chemoimmunotherapy and to stop smoking on the day of cycle 1. He decides who else receives this note. Because Black patients with early lung cancer have less often been offered surgery, the navigator tracks each date against the plan. **S**

## Follow-up

Cycle 1 in eight days; oncology review before each cycle; thoracic surgery review after cycle 2; restaging after cycle 3; Dr. Whitfield-Arroyo continues primary care and shares the monitoring. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Silvestri GA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e211S-e250S (PMID 23649440) (2013), American College of Chest Physicians
- Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013), American College of Chest Physicians
- Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e278S-e313S (PMID 23649443) (2013), American College of Chest Physicians
- Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816). N Engl J Med 2022;386(21):1973-1985 (PMID 35403841) (2022), New England Journal of Medicine
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Schneider BJ, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary. JCO Oncol Pract 2020;16(2):83-86 (PMID 32045555) (2020), American Society of Clinical Oncology
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- Bach PB, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999;341(16):1198-1205 (PMID 10519898) (1999), New England Journal of Medicine
